KaloBios stock slides; to stop asthma study – MarketWatch

KaloBios stock slides; to stop asthma study
MarketWatch
KaloBios Pharmaceuticals Inc.'s (NASDAQ:KBIO) shares slumped after the company said it would discontinue development of a treatment for severe asthma, a move that followed disappointing Phase 2 results. Chief Executive Officer David Pritchard said 
KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma Benzinga

all 2 news articles »

View full post on asthma – Google News

Skyepharma slides as US group ends asthma drug deal – The Guardian


Stockopedia

Skyepharma slides as US group ends asthma drug deal
The Guardian
Shares in Skyepharma have fallen around 5% after another setback for its asthma treatment flutiform. The company has announced that Abbott Laboratories has
SkyePharma loses US partnerGrowthBusiness.co.uk
Abbot shelves interest in SkyePharma's FlutiformShareCast
SkyePharma says Abbott ends US Flutiform dealReuters
Wall Street Journal –Stockopedia
all 8 news articles »

View full post on asthma – Google News